Do analysts rate COCP or ICCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend COCP or ALDX?

Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 307.41%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aldeyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, COCP or ALDX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A

Is COCP or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -53.14% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -207.47% -123.33% Aldeyra Therapeutics N/A -53.14% -34.94%

Do analysts recommend COCP or FBIO?

Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 605.39%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate COCP or NTRB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Cocrystal Pharma (COCP) Competitors

$1.19 -0.02 (-1.65%)

As of 04:00 PM Eastern

Compare

COCP vs. ICCC, ALDX, FBIO, NTRB, and VRCA

Should you buy Cocrystal Pharma stock or one of its competitors? Cocrystal Pharma's main competitors and comparable companies include ImmuCell (ICCC), Aldeyra Therapeutics (ALDX), Fortress Biotech (FBIO), Nutriband (NTRB), and Verrica Pharmaceuticals (VRCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cocrystal Pharma compare to ImmuCell?

Cocrystal Pharma (NASDAQ:COCP) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

ImmuCell has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
ImmuCell	$27.64M	3.33	-$1.04M	$0.08	126.63

ImmuCell has a net margin of 2.57% compared to Cocrystal Pharma's net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
ImmuCell	2.57%	2.69%	1.76%

Cocrystal Pharma has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, ImmuCell had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
ImmuCell	Neutral

Summary

ImmuCell beats Cocrystal Pharma on 10 of the 12 factors compared between the two stocks.

How does Cocrystal Pharma compare to Aldeyra Therapeutics?

Cocrystal Pharma (NASDAQ:COCP) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Aldeyra Therapeutics' return on equity of -53.14% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 307.41%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cocrystal Pharma has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Cocrystal Pharma's average media sentiment score of 0.00 equaled Aldeyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Aldeyra Therapeutics	Neutral

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Summary

Aldeyra Therapeutics beats Cocrystal Pharma on 7 of the 11 factors compared between the two stocks.

How does Cocrystal Pharma compare to Fortress Biotech?

Cocrystal Pharma (NASDAQ:COCP) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Cocrystal Pharma's average media sentiment score of 0.00 equaled Fortress Biotech'saverage media sentiment score.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Fortress Biotech	Neutral

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cocrystal Pharma has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Fortress Biotech	$63.26M	1.27	$6.82M	$2.64	0.91

Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 605.39%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has a net margin of 163.32% compared to Cocrystal Pharma's net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Fortress Biotech	163.32%	83.47%	42.98%

Summary

Fortress Biotech beats Cocrystal Pharma on 11 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to Nutriband?

Cocrystal Pharma (NASDAQ:COCP) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Cocrystal Pharma has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Nutriband's return on equity of -109.07% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Nutriband	-430.35%	-109.07%	-95.54%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Cocrystal Pharma's average media sentiment score of 0.00 equaled Nutriband'saverage media sentiment score.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Nutriband	Neutral

Cocrystal Pharma has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Nutriband has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nutriband has higher revenue and earnings than Cocrystal Pharma. Nutriband is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Nutriband	$2.04M	46.32	-$8.23M	-$0.53	N/A

Summary

Nutriband beats Cocrystal Pharma on 9 of the 11 factors compared between the two stocks.

How does Cocrystal Pharma compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Cocrystal Pharma has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.17	-$17.89M	-$1.67	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

Cocrystal Pharma has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Cocrystal Pharma's return on equity of -207.47% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Cocrystal Pharma	N/A	-207.47%	-123.33%

Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

In the previous week, Verrica Pharmaceuticals' average media sentiment score of 1.40 beat Cocrystal Pharma's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Positive
Cocrystal Pharma	Neutral

Verrica Pharmaceuticals currently has a consensus target price of $12.67, indicating a potential upside of 182.11%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Verrica Pharmaceuticals is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Verrica Pharmaceuticals beats Cocrystal Pharma on 9 of the 14 factors compared between the two stocks.

Get Cocrystal Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCP vs. The Competition

Export

Metric	Cocrystal Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.31M	$12.53B	$7.26B	$12.97B
Dividend Yield	N/A	2.64%	2.53%	12.80%
P/E Ratio	-1.57	789.79	274.69	25.77
Price / Sales	N/A	753.31	647.74	90.25
Price / Cash	N/A	15.08	28.04	34.72
Price / Book	2.59	10.57	10.56	6.36
Net Income	-$8.83M	$2.82B	$3.49B	$358.17M
7 Day Performance	1.71%	-0.36%	-0.23%	0.54%
1 Month Performance	3.48%	-1.19%	-2.80%	-2.95%
1 Year Performance	-10.53%	4.01%	18.25%	6.08%

Cocrystal Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCP Cocrystal Pharma	0.8148 of 5 stars	$1.19 -1.7%	N/A	-11.0%	$23.31M	N/A	N/A	10	Gap Up
ICCC ImmuCell	0.49 of 5 stars	$9.58 -1.3%	N/A	+66.9%	$88.19M	$27.64M	119.76	70	Positive News
ALDX Aldeyra Therapeutics	1.9221 of 5 stars	$1.37 -6.2%	$5.50 +301.5%	-72.4%	$88.08M	N/A	N/A	10	Positive News
FBIO Fortress Biotech	1.718 of 5 stars	$2.49 -1.6%	$17.00 +582.7%	-31.6%	$84.38M	$63.26M	0.94	170
NTRB Nutriband	0.345 of 5 stars	$6.82 -1.6%	N/A	+12.6%	$84.18M	$2.04M	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCP) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cocrystal Pharma (COCP) Competitors

COCP vs. ICCC, ALDX, FBIO, NTRB, and VRCA

How does Cocrystal Pharma compare to ImmuCell?

Summary

How does Cocrystal Pharma compare to Aldeyra Therapeutics?

Summary

How does Cocrystal Pharma compare to Fortress Biotech?

Summary

How does Cocrystal Pharma compare to Nutriband?

Summary

How does Cocrystal Pharma compare to Verrica Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cocrystal Pharma (COCP) Competitors

COCP vs. ICCC, ALDX, FBIO, NTRB, and VRCA

How does Cocrystal Pharma compare to ImmuCell?

Which has stronger earnings and valuation, COCP or ICCC?

Is COCP or ICCC more profitable?

Which has more volatility and risk, COCP or ICCC?

Do analysts rate COCP or ICCC?

Do insiders & institutionals hold more shares of COCP or ICCC?

Does the media prefer COCP or ICCC?

Summary

How does Cocrystal Pharma compare to Aldeyra Therapeutics?

Is COCP or ALDX more profitable?

Do analysts recommend COCP or ALDX?

Which has more volatility and risk, COCP or ALDX?

Does the media favor COCP or ALDX?

Do insiders & institutionals have more ownership in COCP or ALDX?

Which has higher valuation and earnings, COCP or ALDX?

Summary

How does Cocrystal Pharma compare to Fortress Biotech?

Does the media favor COCP or FBIO?

Do institutionals & insiders have more ownership in COCP or FBIO?

Which has more volatility & risk, COCP or FBIO?

Which has better valuation & earnings, COCP or FBIO?

Do analysts recommend COCP or FBIO?

Is COCP or FBIO more profitable?

Summary

How does Cocrystal Pharma compare to Nutriband?

Is COCP or NTRB more profitable?

Do analysts rate COCP or NTRB?

Does the media favor COCP or NTRB?

Which has more risk and volatility, COCP or NTRB?

Do institutionals and insiders hold more shares of COCP or NTRB?

Which has higher earnings and valuation, COCP or NTRB?

Summary

How does Cocrystal Pharma compare to Verrica Pharmaceuticals?

Which has stronger earnings & valuation, VRCA or COCP?

Is VRCA or COCP more profitable?

Which has more volatility and risk, VRCA or COCP?

Does the media prefer VRCA or COCP?

Do analysts rate VRCA or COCP?

Do institutionals & insiders believe in VRCA or COCP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools